TITLE

A phase II study of oral etoposide in elderly patients with small cell lung cancer

AUTHOR(S)
Smit, E F; Carney, D N; Harford, P; Sleijfer, D T; Postmus, P E
PUB. DATE
August 1989
SOURCE
Thorax;Aug1989, Vol. 44 Issue 8, p631
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66098915

 

Related Articles

  • Lung Cancer in the Elderly: Current and Future Chemotherapeutic Options. Hinton, S.; Sandler, A. // Drugs & Aging;2002, Vol. 19 Issue 5, p365 

    Lung cancer is a prevalent malignancy disproportionately affecting the elderly, and in our aging societies will only increase in magnitude. Physicians typically assume that elderly lung cancer patients will have poorer prognoses. This belief is in part based on certain physiological changes of...

  • OSI / Genentech / Roche: Tarceva triumphs again.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p9 

    The article reports that The results of a phase II study have suggested that OSI Pharmaceuticals Inc., Genentech Inc. and the company Roche AG's cancer drug, Tarceva may be particularly beneficial in elderly patients with previously untreated lung cancer. The results of the phase II trial...

  • Re: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized... Pfeiffer, Per; Rytter, Carsten; Madsen, Ebbe Lindegaard; Moeholt, Kirsten; Hansen, Olfred; Bentzen, Soren; Palshof, Torben; Rose, Carsten // JNCI: Journal of the National Cancer Institute;12/17/97, Vol. 89 Issue 24, p1892 

    Investigates whether single-agent, daily, oral etoposide is an effective, palliative therapy for advanced small-cell lung cancer as compared with combination therapy. Bioavailability of oral etoposide; Comparison of tumor response to oral etoposide and combination therapy in patients with...

  • A Phase II Study of VP-16-Ifosfamide-Cisplatin Combination Chemotherapy Plus Early Concurrent Thoracic Irradiation for Previously Untreated Limited Small Cell Lung Cancer. Sook Woo; Woo, In Sook; Young Suk Park; Park, Young Suk; Sung Hee Kwon; Kwon, Sung Hee; Park, Young Iee; Young Lee Park; Lee, Jung Ae; Jung Ae Lee; Park, Myung Jae; Myung Jae Park; Hyun, In Gyu; In Gyu Hyun; Jung, Ki Suk; Ki Suk Jung; Bae, Hoon Sik; Hoon Sik Bae; Oh, Do Hoon; Do Hoon Oh // Japanese Journal of Clinical Oncology;Dec2000, Vol. 30 Issue 12, p542 

    Presents a phase II study of etoposide (VP-16)-ifosfomide-cisplatin(VIP) combination chemotherapy plus early concurrent thoracic irradiation for patients with untreated small cell lung cancer to assess the improvement in the response rate and toxicity. Effects of early and late thoracic...

  • Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison... Souhami, Robert L.; Spiro, Stephen G. // JNCI: Journal of the National Cancer Institute;04/16/97, Vol. 89 Issue 8, p577 

    Determines if the effects of oral etoposide therapy on survival and quality of life are equivalent to those of intravenous chemotherapy. Comparison of randomized trial of palliative treatment in advance small-cell lung cancer (SCLC), oral etoposide and intravenous chemotherapy; Tumor response...

  • Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Sakakibara, T.; Inoue, A.; Sugawara, S.; Maemondo, M.; Ishida, T.; Usui, K.; Abe, T.; Kanbe, M.; Watanabe, H.; Saijo, Y.; Nukiwa, T. // Annals of Oncology;Apr2010, Vol. 21 Issue 4, p795 

    Background: The optimal platinum doublet regimen in elderly patients with non-small-cell lung cancer (NSCLC) is still uncertain. We conducted a randomized phase II study to compare the efficacy and safety of weekly paclitaxel combined with carboplatin with those of the standard schedule.

  • Aeterna completes enrollment for Phase II trial of lung cancer.  // PharmaWatch: Cancer;Jan2008, Vol. 7 Issue 1, p18 

    The article reports that Aeterna Zentaris Inc. has completed patient recruitment for its European multi-center Phase II trial in non-small cell lung cancer with perifosine. The study will assess the efficacy and safety of a 150 milligram daily dose of perifosine when combined with radiotherapy...

  • Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer. Reck, Martin; von Pawel, Joachim; Macha, Hans-Nicolas; Kaukel, Eckhard; Deppermann, Karl-Matthias; Bonnet, Reiner; Ulm, Kurt; Hessler, Sybill; Gatzemeier, Ulrich // JNCI: Journal of the National Cancer Institute;8/06/2003, Vol. 95 Issue 15, p1118 

    Cites the results of a randomized phase III trial from 1998 to 1999 comparing the efficacy of carboplatin, etoposide and paclitaxel and of vincristine, etoposide and carboplatin in treating small-cell lung cancer. Patient eligibility; Treatment protocol; Treatment evaluations and statistical...

  • Chemotherapy and Radiotherapy.  // Current Medical Literature: Lung Cancer;2012, Vol. 5 Issue 3, p82 

    The article discusses several studies on chemotherapy and radiotherapy as treatment options for lung cancer. Researchers from Royal Marsden Hospital investigated the use of amrubicin as single-agent or in combination with cisplatin versus cisplatin etoposide as first-line therapy in patients...

  • OSI / Genentech / Roche: Tarceva triumphs again.  // PharmaWatch: Biotechnology;Nov2005, Vol. 4 Issue 11, p4 

    The article focuses on a study regarding the effect of Tarceva drugs in the treatment of cancer in the elderly patients. It has suggested that the Tarceva drug manufactured by OSI Pharmaceuticals Inc., Genentech Inc. and Roche may be particularly beneficial in elderly patients with previously...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics